Tenet trades like a hospital chain. Half its profits don't act like one.

• Two engines, one wrapper. USPI's 533 ambulatory surgery centers earn a 39.2% segment EBITDA margin and grew same-facility revenue 7.5% in FY2025 — nearly half of consolidated EBITDA on a quarter of the revenue. The 50-hospital book, clustered in TX, FL, AZ and MI, earns 15.7% and grows admissions at 1–2%.
• The SOTP gap. USPI alone, at the only listed pure-play's 9.4x EBITDA, is worth $18–22B. Add the hospital book at 6x ($15B), Conifer ($1.5B), subtract $10.3B of net debt and minority interests, and the parts mark to $19–27B against a $17B market cap.
• Why the discount sticks. USPI promised 575–600 ASCs by FY2025 and delivered 533 — a 7–12% miss that lets the market keep pricing the consolidated entity at 7.9x EV/EBITDA versus HCA at 9.2x and pure-play SGRY at 9.4x.

Five years rebuilt the math. Leverage halved, margins doubled, the float thinned.

Before (2018): A 65-hospital chain with $15B of debt, 6.4x net leverage, and a 12.5% adjusted EBITDA margin. The Street had given up; the equity was a leveraged option on hospital admissions in a year when admissions were flat.

Pivot (2020–2024): Two CEOs ran one playbook — divest weak hospitals, scale USPI, deleverage. Fourteen hospitals were sold across SC, CA and AL for over $5B; $2B of debt was repaid; the Conifer JV was reset in January 2026 for $540M plus $1.9B of accelerated cash. Sutaria took the chair in September 2021 with no strategy drift across the handoff.

Today: 50 hospitals, 533 ASCs, a 21.4% adjusted EBITDA margin, 2.25x net debt, $2.5B of free cash flow, and 16% of shares retired since FY2022. The next chapter answers one question — does the reset margin survive the policy stack of 2026–2028?

$2.5B of free cash, but a third leaves before it reaches shareholders.

The headline isn't the cleanest number. After ~$700M of physician-JV minority distributions and a $1.9B Conifer cash inflow that runs through 2028, durable owner-level FCF guides to $1.6–1.83B in FY2026 — a 10% yield, not the 15% a passive screen reads. The flywheel is real; the buyback deserves to compound the right number.

The accounting is GAAP-clean. The signals around it are not.

• FY2024 gain inside operating income. A $2.916B "net gains on sales" line sits above the operating-income line, lifting reported FY2024 op income from a normalized $3.0B to $5.7B. Anyone comparing reported FY2024 to FY2025 misreads sustainable margin by 51%.
• An active SEC enforcement matter. A June 2025 short report cited a FOIA response invoking the 7(A) exemption, indicating an open SEC enforcement file, with alleged Medicare/Medicaid exposure of $675–845M. Tenet's history includes a $513M False Claims settlement in 2022 and a $10M SEC fraud settlement in 2007.
• Accounting leadership in transition. The long-serving Principal Accounting Officer retired April 30, 2026; the new PAO took over May 1. PAO handovers are the textbook moment for deferred reserve adjustments to surface — H2 2026 disclosures are the first read.

Consensus froze FY2027 EPS one cent above FY2026. The math doesn't.

• What the Street did. Eighteen sell-side analysts hold FY2027 EPS at $17.76 against $17.72 in FY2026 — implicitly assuming an unsized 2027 OBBBA Medicaid hit ($300–500M) cancels out the buyback math and USPI mix-shift in the same year. Each piece is plausible alone; the joint probability isn't.
• The mechanical view. $1.4B of annual buybacks against a $17B cap retires ~7–8% of float per year; USPI's commercial-and-Medicare mix is structurally insulated from Medicaid policy. On those two alone, FY2027 EPS prints $1.50–$2.00 above the line — roughly $25–$30 of fair value at a 16x multiple.
• What resolves it. Q2 2026 earnings (late July) is the first clean read on whether USPI same-facility growth holds 5%+ and whether hospital revenue per adjusted admission stops decelerating from Q1's –1.5%. CMS/Treasury OBBBA implementation rules drop in H2 2026 and size the 2027 hit. Both arrive inside the next six months.